Evaxion Biotech Q2 EPS $(0.21) Down From $(0.20) YoY
Portfolio Pulse from Benzinga Newsdesk
Evaxion Biotech reported Q2 losses of $(0.21) per share, a 5% decrease YoY. The company's cash and cash equivalents were $7.1 million as of June 30, 2023, compared to $13.2 million as of December 31, 2022. The company expects its existing cash to fund operating expenses and capital expenditure requirements into December 2023.
August 17, 2023 | 8:53 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Evaxion Biotech reported a YoY decrease in Q2 losses and a decrease in cash and cash equivalents. The company expects its existing cash to fund operations into December 2023.
The increase in losses and decrease in cash and cash equivalents could negatively impact investor sentiment, potentially leading to a decrease in the short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100